LJI launches new global cancer immunology resource

The National Cancer Institute (NCI) of the National Institutes of Health has granted over $4.2 million to launch the Cancer Epitope Database and Analysis Resource (CEDAR), led by La Jolla Institute for Immunology (LJI) Professors Alessandro Sette,...
2-Jun-2021 1:55 PM EDT Add to Favorites

LJI and Synbal, Inc. partner to develop better COVID-19 models

The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by...
27-May-2021 6:05 PM EDT Add to Favorites

A COVID-fighter’s guide to T cells

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus.
25-May-2021 12:15 PM EDT Add to Favorites

Shape-shifting Ebola virus protein exploits human RNA to change shape

In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new...
14-Apr-2021 11:10 AM EDT Add to Favorites

A clue to how some fast-growing tumors hide in plain sight

Viruses churn out genetic material in parts of the cell where it's not supposed to be. Cancer cells do too. A new study shows that a tumor-suppressor enzyme called DAPK3 is an essential component of a multi-protein system that senses misplaced...
22-Mar-2021 8:20 AM EDT Add to Favorites

Erica Ollmann Saphire appointed president and CEO of La Jolla Institute for Immunology

Erica Ollmann Saphire, Ph.D., has been appointed President and CEO of La Jolla Institute for Immunology (LJI), the Institute announced today. Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on...
16-Mar-2021 2:00 PM EDT Add to Favorites

LJI research leads to promising combination therapy for type 1 diabetes

Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.
9-Mar-2021 11:40 AM EST Add to Favorites

Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement

La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer...
23-Feb-2021 1:55 PM EST Add to Favorites

See All News